地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：18372041646
传真：18771997407
邮箱：sales@amyjet.com
<艾美捷科技代理Terracebiotech品牌全系列产品
Terracebiotech的专业技术源于加州大学旧金山分校医学中心的肺研究小组，该小组曾助力明确肺表面活性物质的特性，随后研发出其合成形式，用于治疗患有呼吸窘迫综合征的早产儿。凭借在肺细胞生物学领域超过 25 年的实践研究经验，Terracebiotech将其专业技术应用于推动医学研究的进一步创新，以改善人类健康。
Terracebiotech的抗体（在人体肺部中特异性靶向肺泡上皮1型或2型细胞）经验证，可高效、可靠地用于以下应用：免疫组织化学 (IHC)；蛋白质印迹法 (Western Blotting)；通过流式细胞分选技术 (FACS) 进行细胞分离；半定量斑点印迹 (Semi-Quantitative Dot Blots)；磁性细胞分选 (Magnetic Cell Sorting)；冷冻免疫电镜 (TEM Cryo-Immunohistochemistry)。
▍Terracebiotech产品列表
| 品名 | 货号 | Validated For | Production Host | Isotype | 规格 |
| Anti HT1-56 | TB-29AHT1-56 | IHC, Western Blots, FACS, magnetic Cell Sorting, Dot blots, and TEM | Mouse hybridoma cells | Mouse IgG1 | 1ml |
| Anti HT2-280 | TB-27AHT2-280 | IHC, Western Blots, FACS, magnetic Cell Sorting, Dot blots, and TEM | Mouse hybridoma cells | Mouse IgM | 1ml |
| Anti RT1-40 | TB-11ART1-40 | IHC, Western Blots, FACS, magnetic sell sorting, and dot blots. | Mouse hybridoma cells | Mouse IgG1 | 1ml |
| Anti RT2-70 | TB-44ART2-70 | IHC, FACS, magnetic Cell Sorting, and dot blots. | Mouse hybridoma cells | Mouse IgG3 | 1ml |
艾美捷科技代理Absolute Antibody重组抗体。
Absolute Antibody成立于2012年，其产品线100%专注于重组抗体。虽然重组抗体是制药行业的主流，但这些抗体尚未广泛用于诊断或研究。由于重组抗体比传统杂交瘤产生的单克隆抗体
具有许多优势，这种情况正在开始改变。
Absolute Antibody专注于抗体测序、抗体工程和抗体重组表达，并提供定制服务、重组抗体和Fc融合蛋白。Absolute Antibody的客户包括制药公司、生物技术和诊断公司，以及世界各
地的学术研究人员。此外，Absolute Antibody团队在治疗性抗体和重组表达技术领域拥有丰富的经验。自成立以来，Absolute Antibody已生产了180多种不同构型的抗体，并开发了逾
15000种重组抗体试剂。
Chemicell公司位于德国柏林，该公司主要进行创新的以纳米级磁珠为基础的生物分离、基因转染&检测系统开发和生产工作。开发的重点在于设计以客户为导向特别兼容了实验室自动化的即用型试剂盒。
chemicell develops and produces innovative bioseparation- gene transfection and detection systems based on magnetic nano- and microparticles. Focus of our product development is to design high quality customer-oriented "ready-to use" kits with special orientation towards the compatibility for labor automatisation. It is chemicell's policy to be open for cooperations with other companies or scientific institutes to maximize the chances and opportunities that evolve from the rapid development of biotechnological procedures and to distribute innovative new products.
主要产品包括：
Magnetofection™
Biomagnetic Separation
Magnetic Microparticles
Magnetic-Fluorescent Microparticles
Magnetic Nanoparticles
Magnetic-Fluorescent Nanoparticles
Microspheres-Non-Magnetic
Silica Microspheres-Non-Magnetic
Silica Fluorescent Microspheres-Non-Magnetic
Magnetic Separators
DNA / RNA Purification
PEG derivates
" data-original="http://atto.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Chemicell"> Chemicell
Transgenomic目前隶属于Thermo Fisher,致力于服务心脏疾病、肿瘤和遗传疾病的个体化用药研究领域。
Transgenomic的主要产品包括：
ADS Biotec Inc WAVE BUFFER A 2.5L 4/CS
ADS Biotec™ Optimase™ DNA Polymerase
CE Phosphoramidites from Cruachem
Cruachem™ Oligomimetics and Modified Oligonucleotides
Transgenomic Ancillary Reagents for DNA Synthesis For Cyclone™ and Expedite™
Specialized CE Phosphoramidites from Cruachem
Transgenomic DNA Synthesis Ancillary Reagents For Biosearch 8000 Series
ADS Biotec Inc 5-FLUORO DU
ADS Biotec Inc 5'TAMRA-3'-DABCYL等等
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://atto.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Transgenomic"> Transgenomic
<艾美捷科技代理Helvetica Health Care品牌全系列产品
Helvetica Health Care是一家位于瑞士日内瓦的医疗保健公司，致力于通过创新的产品和技术来管理健康和提高生活质量。作为瑞士生物技术协会的成员，Helvetica Health Care通过了ISO 13485认证，在质量和创新方面坚持最高标准。涵盖各种质量控制和验证面板，适用于不同的分子测试平台和检测。这些产品有多种规格，可用于单一或多种分析物的检测，帮助实验室监控测试性能，确保测试的准确性和可靠性。其质量控制和验证组合可根据产品配置、填充量和分析物浓度进行定制，满足不同平台的需求。
▎Helvetica Health Care产品线
Helvetica Health Care公司的产品涵盖：抗体、生命科学产品、血液分离产品、临床/诊断样本、质控品与标准品、分子生物学产品、细胞因子与生长因子、ELISA试剂盒/Western印迹相关产品、微生物、氧化应激产品、诊断产品以及人血浆制品。
▎Helvetica Health Care部分产品列表
| 货号 | 产品描述 |
| NATFRC-6C | NATtrol Flu/RSV/SARS-CoV-2 Positive Control (6 x 0.5mL) |
| NATCV9-6C | NATtrol Flu/RSV/SARS-CoV-2 Negative Control (6 x 0.5mL) |
| NATRPC2.1-BIO | NATtrol Respiratory Panel 2.1 (RP2.1) Controls (12 x 0.3mL) |
| NATRVP2.1-BIO | NATtrol Respiratory Verification Panel 2.1 (24 x 0.6mL) (EA) |
| NATRVP2.1-BIO Plus | NATtrol Respiratory Verification Panel 2 Plus (+NATCOV(MR)-BIO) (24x 0.6 ml + 1x 0.6 ml) |
| NATRVP2-QIA | NATtrol Respiratory Verification Panel 2 (21 x 0.25mL) (EA) |
| NATSARS(COV2)-VP | NATtrol SARS-CoV-2 Variant Panel (4 x 0.5mL) |
| NATSARS(COV2)-ERC | SARS-Related Coronavirus 2 (SARS-CoV-2) External Run Control (6 x 0.5 mL) |
| NATSARS(COV2)-ERC1 | NATtrol SARS-Related Coronavirus 2 (SARS-COV-2) Positive Control (6x 1.0 ml) |
| NATSARS(COV2)-NEG | SARS-Related Coronavirus 2 (SARS-CoV-2) Negative Control (6 x 0.5 mL) |
| NATSARS(COV2)-NEG1 | NATtrol SARS-Related Coronavirus 2 (SARS-COV-2) Negative Control (6x 1.0 ml) |
| NATSARS(COV2)-ST | SARS-Related Coronavirus 2 (SARS-CoV-2) Stock |
| NATSARS(COV2-SA)-ST | NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.351 Stock (1mL) |
| NATSARS(COV2-UK)-ST | NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.1.7 Stock (1mL) |
| 0810229-0.5mg | Coronavirus 229E Lysate (0.5 mg) |
| 0810587 | SARS-CoV-2 (Isolate: USA-WA1/2020) Lysate (1 mg) |
| 0810587-0.5mg | SARS-CoV-2 (Isolate: USA-WA1/2020) Lysate (0.5 mg) |
| 0810587CFHI-0.5mL | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (Heat Inactivated) (0.5 mL) |
| 0810587CFHI | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (Heat Inactivated) (1.0 mL) |
| 0810587UV | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (UV Inactivated) (1 mL) |
| 0810589CFHI | SARS-CoV-2 (Isolate: Italy-INMI1) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810589UV | SARS-CoV-2 (Isolate: Italy-INMI1) Culture Fluid (UV Inactivated) (1 mL) |
| 0810590CFHI | SARS-CoV-2 (Isolate: Hong Kong/VM20001061/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810590UV | SARS-CoV-2 (Isolate: Hong Kong/VM20001061/2020) Culture Fluid (UV Inactivated) (1 mL) |
| 0810617UV | SARS-CoV-2 Lineage P1_2021; Gamma Variant (NY-Wadsworth-21033899-01/2021) Culture Fluid (UV)) |
| 0810618UV | SARS-CoV-2 Lineage P2_2021; Zeta Variant (NY-Wadsworth-21006055-01/2021) Culture Fluid (UV) |
| 0810619UV | SARS-CoV-2 Iso1 Lin B.1.526_2021 Iota (NY-Wadsworth-21025952-01/2021) CF (UV Inactivated) |
| 0810620UV | SARS-CoV-2 Iso2 Lin B.1.526_2021 Iota (NY-Wadsworth-21025952-01/2021) CF (UV Inactivated) |
| 0810621UV | SARS-CoV-2 Lineage B.1_2020 (NY-Wadsworth-103677-01/2020) CF (UV Inactivated) |
| 0810622UV | SARS-CoV-2 Lineage B.1.595_2020 (NY-Wadsworth-33126-01/2020) CF (UV Inactivated) |
| 0810612CFHI | SARS-CoV-2 Variant B.1.1.7 (Isolate:USA/CA_CDC_5574/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810612UV | SARS-CoV-2 Lineage B.1.1.7; Alpha Variant (USA/CA_CDC_5574/2020) CF (UV Inactivated) (1 mL) |
| 0810613CFHI | SARS-CoV-2 Variant B.1.351(Isolate:South_Africa/KRISP-K005325/2020) CF (Heat Inactivated) (1 mL) |
| 0810613UV | SARS-CoV-2 Lineage B.1.351; Beta (South_Africa/KRISP-K005325/2020) CF (UV Inactivated) (1 mL) |
| 0810614CFHI | SARS-CoV-2 Variant B.1.1.7 (Isolate:England/204820464/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810614UV | SARS-CoV-2 Lineage B.1.1.7 Alpha Variant (England/204820464/2020) CF (UV Inactivated) (1 mL) |
| 0810616CFHI | SARS-CoV-2 Lineage P1; Gamma Variant (Japan/TY7-503/2021) CF (Heat Inactivated) (1 mL) |
| 0810616UV | SARS-CoV-2 Lineage P1; Gamma Variant (Isolate: Japan/TY7-503/2021) CF (UV Inactivated) (1 mL) |
| 0810617CFHI | SARS-CoV-2 Lineage P1_2021; Gamma Variant (NY-Wadsworth-21033899-01/2021) – CFHI (1.0 ml) |
| 0810618CFHI | SARS-CoV-2 Lineage P2_2021; Zeta Variant (NY-Wadsworth-21006055-01/2021) – CFHI (1.0 ml) |
| 0810619CFHI | SARS-CoV-2 Lso1 Lin B.1.526_2021 Lota (NYWadsworth-21025952-01/2021) – CFHI (1.0 ml) |
| 0810620CFHI | SARS-CoV-2 Lso2 Lin B.1.526_2021 Lota (NYWadsworth-21025952-01/2021) – CFHI (1.0 ml) |
| 0810621CFHI | SARS-CoV-2 Lineage B.1_2020 (NY-Wadsworth-103677-01/2020) – CFHI (1.0 ml) |
| 0810622CFHI | SARS-CoV-2 Lineage E3.1.595J2020 (NYWadsworth-33126-01/2020) – CFHI (1.0 ml) |
| 0810623UV | SARS-CoV-2 Lineage B.1.617.1 Kappa Variant (USA/CA-Stanford-15_S02/2021) CF (UV Inactivated) |
| 0810623CFHI | SARS-CoV-2 Lineage B.1.617.1 Kappa Variant (USA/CA-Stanford-15_S02/2021) CF (Heat Inactivated) |
| 0810624UV | SARS-CoV-2 Lineage B.1.617.2; Delta Variant (USA/PHC658/2021) CF (UV Inactivated) |
| 0810624CFHI | SARS-CoV-2 Lineage B.1.617.2; Delta Variant (USA/PHC658/2021) CF (Heat Inactivated) |
| 0820010CFHI | VeroE6 Culture Fluid (Heat Inactivated) (1 mL) |
| 0801043 | Goat Anti-SARS-CoV-2 Polyclonal Serum (0.5 ml) |
| 0831042 | SARS-CoV-2 (recombinant) Stock (1 x 1.0 mL) |
| 0831043 | SARS-CoV-2 (E/ORF1ab recombinant) Stock (1 x1.0mL) |
| NATSARS-ST | Coronavirus SARS Stock (Qualitative) (1 mL) |
| NATCOV(229E)-ST | Coronavirus 229E Stock (Qualitative) (1 mL) |
| 0810229CFHI | Coronavirus (Strain: 229E) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810229 | Coronavirus Strain: 229E Lysate |
| 0810229UV | Coronavirus (Strain: 229E) Culture Fluid (UV Inactivated) (1 mL) |
| NATCOV(NL63)-ST | Coronavirus NL63 Stock (Qualitative) (1 mL) |
| 0810228CFHI | Coronavirus (Strain: NL63) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810228 | Coronavirus Strain: NL63 Lysate |
| 0810228UV | Coronavirus (Strain: NL63) Culture Fluid (UV Inactivated) (1 mL) |
| NATCOV(OC43)-ST | Coronavirus OC43 Stock (Qualitative) (1 mL) |
| 0810024CFHI | Coronavirus (Strain: OC43) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810024 | Coronavirus Strain: OC43 Lysate |
| NATMERS-ST | MERS-CoV Stock (Qualitative) (1 mL) |
| NATMR-BIO | NATtrol MERS Recombinant Pack (2x 0.2 ml +0.5 ml) |
| NATCOV(MR)-BIO | NATtrol MERS-S. Cerevisiae (0.6 ml) |
| 0810575 | MERS-COV (Strain: Florida/USA-2_Saudi Arabia_2014) Lysate(1mg) |
| 0810575-0.5mg | MERS-COV (Strain: Florida/USA-2_Saudi Arabia_2014) Lysate(0.5mg) |
| CV033122 | COVID-19 Cross Over Panel (40x 1.0 ml) |
<Nanostructured & Amorphous Materials, Inc.致力于纳米材料科技的应用。主要的业务包括：生产、研发、加工纳米级和非结晶材料。
Nanostructured & Amorphous Materials Inc. (NanoAmor) was founded in Los Alamos, New Mexico, USA, in September 2001. We are a leading nanomaterials company involved in all aspects of the business: manufacturing, research and development, processing, supplying and marketing of nanostructured materials and their dispersions.
Nanostructured & Amorphous Materials的主要产品包括：
Application-Oriented Carbon-Nanotubes Products
Carbon Nanotubes & Nanofibers
Carbon Nanotube Dispersions
Elements, Oxides, Carbides & Nitrides Nanoparticles
Fullerene
Graphenes, Graphene Oxides & Graphene Nanoplatelets
Graphene Film
Nanopowder Dispersions
Nanowires & Nanorods
Amorphous Ribbons
Nanocrystalline Ribbons
Amorphous & Nanocrystalline Cores
Amorphous and Nanocrystalline Magnetic Bars
Amorphous & Nanocrystalline Powders
Amorphous Brazing Foils
Superhard Materials
Surface-Modified Oxide Nanoparticles
| 品名 | 货号 | 规格 |
| CNTs Additives for Lithium-ion Battery | 1376YJ | 1kg; |
| Carbon Nanotubes Fibers | 1356YJ | meter; |
| Carbon Nanotubes Papers | 1348YJ | piece; |
| Carbon Nanotubes Films | 1350YJ | piece; |
| Carbon Nanotubes Films | 1351YJ | 咨询 |
| Water-based carbon nanotubes coatings | 1332YJ | kg; |
| Water-based carbon nanotubes coatings | 1333YJ | kg; |
| Antistatic carbon-nanotubes coatings | 1331YJA | kg; |
| Antistatic carbon-nanotubes coatings | 1331YJB | kg; |
| Conductive/heating carbon-nanotubes coatings | 1378YJA | kg; |
| 20wt% CNTs/80wt% ABS Masterbatch | 1335YJ | 1kg; 5kg; 10kg; |
| 25wt% CNTs/75wt% HDPE Masterbatch | 1337YJ | 1kg; 5kg; 10kg; |
| 25wt% CNTs/75wt% HIPS Masterbatch | 1338YJ | 1kg; 5kg; 10kg; |
| 25wt% CNTs/75wt% LLDPE Masterbatch | 1339YJ | 1kg; 5kg; 10kg; |
| 20wt% CNTs/80wt% PA6 Masterbatch | 1340YJ | 1kg; 5kg; 10kg; |
| 20wt% CNTs/80wt% PP Masterbatch | 1341YJ | 1kg; 5kg; 10kg; |
| 0.2 wt% SWCNTs (> 95%, D < 2 nm)/Water Dispersion | 8040YJ | 500g; |
| 0.2 wt% SWCNTs-COOH (> 95%, OD 1-2 nm)/Water Dispersion | 8042YJ | 500g; |
| 2 wt% MWCNTs (> 98%, D 5-15 nm)/Water Dispersion | 8028YJ | 500ml; |
| 2 wt% MWCNTs-COOH (> 98%, D 5-15 nm)/Water Dispersion | 8027YJ | 500 ml; |
| 10 wt% MWCNTs (> 98%, D 30-80 nm)/Water Dispersion | 8030YJ | 500 ml; |
| 10 wt% MWCNTs-COOH (>98%, D 30-80 nm)/Water Dispersion | 8029YJ | 500 ml; |
| 0.2 wt% SWCNTs (> 95%, D < 2 nm)/Water Paste | 8038YJ | kg; |
| 0.2 wt% SWCNTs-COOH (> 95%, OD 1-2 nm)/Water Paste | 8039YJ | 500g; kg; |
| 2 wt% MWCNTs (> 95%, D 5-15 nm)/Water Paste | 8032YJ | kg; |
| 2 wt% MWCNTs-COOH (> 95%, D 5-15 nm)/Water Paste | 8033YJ | kg; |
| 10 wt% MWCNTs (> 95%, D 30-80 nm)/Water Slurry | 8034YJ | kg; |
| 10 wt% MWCNTs-COOH (> 95%, D 30-80 nm)/Water Paste | 8035YJ | kg; |
| 12-14 wt% MWCNTs (> 95%, D 30-80 nm)/Water Paste | 8036YJ | kg; |
| 12-14 wt% MWCNTs-COOH (>95%, D 30-80 nm)/Water Paste | 8037YJ | kg; |
| 0.2-0.3 wt% SWCNTs (> 95%, D 1-2 nm)/BA Dispersion | 8116YJ | 500 ml; |
| 0.2-0.3 wt% SWCNTs (> 95%, D 1-2 nm)/DMAC Dispersion | 8118YJ | 500 ml; |
| 0.2-0.3 wt% SWCNTs (> 95%, D 1-2 nm)/DMF Dispersion | 8115YJ | 500 ml; |
| 0.2-0.3 wt% SWCNTs (> 95%, D 1-2 nm)/IPA Dispersion | 8117YJ | 500 ml; |
| 0.2-0.3 wt% SWCNTs (> 95%, D 1-2 nm)/NMP Dispersion | 8114YJ | 500 ml; |
| 3 wt% MWCNTs (> 98%, D 5-15 nm)/BA Dispersion | 8124YJ | 500 ml; |
| 8-10 wt% MWCNTs (> 98%, D 30-80 nm)/BA Dispersion | 8123YJ | 500 ml; |
| 3 wt% MWCNTs (> 98%, D 5-15 nm)/DMAC Dispersion | 8126YJ | 500 ml; |
| 10 wt% MWCNTs (> 98%, D 30-80 nm)/DMAC Dispersion | 8125YJ | 500 ml; |
| 3 wt% MWCNTs (> 98%, D 5-15 nm)/DMF Dispersion | 8122YJ | 500 ml; |
| 10 wt% MWCNTs (> 98%, D 30-80 nm)/DMF Dispersion | 8121YJ | 500 ml; |
| 3 wt% MWCNTs (> 98%, D 5-15 nm)/IPA Dispersion | 8130YJ | 500 ml; |
| 8-10 wt% MWCNTs (> 98%, D 30-80 nm)/IPA Dispersion | 8129YJ | 500 ml; |
| 3 wt% MWCNTs (> 98%, D 5-15 nm)/NMP Dispersion | 8120YJ | 500 ml; |
| 5 wt% MWCNTs (> 98%, D 30-80 nm)/NMP Dispersion | 8119YJ | 500 ml; |
| 3 wt% MWCNTs (> 98%, D 5-15 nm)/PMA Dispersion | 8128YJ | 500 ml; |
| 10 wt% MWCNTs (> 98%, D 30-80 nm)/PMA Dispersion | 8127YJ | 500 ml; |
| Fullerence powder (C60, 95+%) | 8072YJ | 1g; 5g; |
| Fullerence powder (C60, 98+%) | 8073YJ | 1g; 5g; |
| Fullerence powder (C60, 99+%) | 8074YJ | 1g; 5g; |
| Fullerene powder (C60, 99.5+%) | 8075YJ | 1g; 5g; |
| Fullerene powder (C60, 99.9+%) | 8076YJ | 1g; 5g; |
| Fullerence powder (C70, 95+%) | 8077YJ | 1g; 5g; |
| Fullerence powder (C70, 98+%) | 8078YJ | 1g; 5g; |
| Fullerence powder (C70, 99+%) | 8079YJ | 1g; 5g; |
| Fullerenol Powder (hydroxylated fullerence C60) | 8080YJ | 1g; 10g; |
| Three-Dimensional Graphene (> 60 wt%, D 6-8 um, 3-4 layers) | 8109YJ | 1g; 5g; |
| 1.0-1.5 wt% Graphenes (> 98 wt%, Dia. 4-6 um, < 10 layers)/NMP paste | 8064YJ | 1g (graphene); 5g (graphene); |
| Highly Elastic Graphene Aerogel (Dia. 2.0 cm, Height 2.0 cm) | 8095YJ | 1 cylinder; 5 cylinders; |
| Ultra-light Graphene Aerogel (Dia. 2.0 cm, Height 2.0 cm) | 8093YJ | 1 cylinder; 5 cylinders; |
| Carbon Nanotubes (10 wt%) Doped Graphene Aerogel (Dia. 1.2 cm, Height 1.2 cm) | 8090YJ | 1 cylinder; 5 cylinders; |
| Carbon Nanotubes (10 wt%) Doped Graphene Aerogel (Dia. 2.0 cm, Height 2.0 cm) | 8091YJ | 1 cylinder; 5 cylinders; |
| Magnetic Graphene Aerogel (47 wt% Fe3O4, Dia. 1 cm, Height 1 cm) | 8096YJA | 1 cylinder; 5 cylinders; |
| Magnetic Graphene Aerogel (47 wt% Fe3O4, Dia. 2 cm, Height 2 cm) | 8096YJB | 1 cylinder; 5 cylinders; |
| Magnetic Graphene Aerogel (63 wt% Fe3O4, Dia. 1 cm, Height 1 cm) | 8097YJA | 1 cylinder; 5 cylinders; |
| Magnetic Graphene Aerogel (63 wt% Fe3O4, Dia. 2 cm, Height 2 cm) | 8097YJB | 1 cylinder; 5 cylinders; |
| Graphene Foam on Nickel Foam (thickness 1-1.2 mm) | 1319YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| Graphene Foam (nickel foam etched, thickness 1-1.2 mm) | 1320YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| 1-3 wt% Graphene Oxide (> 98 wt%, D 1-5 um, 1-2 layers)/Water Gel, pH = 3-4 | 8047YJB34 | 1g (graphene oxide); 5g (graphene oxide); |
| Graphene Oxide Paper (Dia. 9 cm, thickness 10 um) | 8089YJ | 1 piece; 5 pieces; |
| Industrial-Grade Graphene Nanoplatelets (> 90 wt%, D 2-13 um, < 30 layers) | 8055YJ2 | 50g; 250g; 1kg; |
| 5 wt% Graphene Nanoplatelets (> 90 wt%, D 2-16 um, < 30 layers)/NMP Paste | 8059YJ | kg (paste); |
| Industrial-Grade Graphene-Nanoplatelets/Carbon-Nanotubes Composites (> 90 wt%) | 8071YJ | 50g; 100g; |
| 5 wt% (Graphene Nanoplatelets & Carbon Nanotubes)/Water Paste | 8060YJ | kg (paste); |
| 5 wt% (Graphene Nanoplatelets & Carbon Nanotubes)/NMP Paste | 8061YJ | kg (paste); |
| Singled-layered graphene on copper substrate, > 97% area covered | 1301YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; 10 cm x 10 cm; |
| Singled-layered graphene on copper substrate, > 97% area covered | 1301YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; 10 cm x 10 cm; |
| Singled-layered graphene on copper substrate, > 97% area covered | 1301YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; 10 cm x 10 cm; |
| Singled-layered graphene on copper substrate, > 97% area covered | 1301YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; 10 cm x 10 cm; |
| Singled-layered graphene on copper substrate, > 97% area covered | 1301YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; 10 cm x 10 cm; |
| Singled-layered graphene on copper substrate, > 97% area covered | 1301YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; 10 cm x 10 cm; |
| Singled-layered graphene on copper substrate, > 97% area covered | 1301YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; 10 cm x 10 cm; |
| Singled-layered graphene on copper substrate, > 85% area covered | 1302YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on copper substrate, > 85% area covered | 1302YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on copper substrate, > 85% area covered | 1302YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on copper substrate, > 85% area covered | 1302YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on copper substrate, > 85% area covered | 1302YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on copper substrate, > 85% area covered | 1302YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on copper substrate, > 85% area covered | 1302YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on copper substrate | 1303YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on copper substrate | 1303YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on copper substrate | 1303YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on copper substrate | 1303YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on copper substrate | 1303YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on copper substrate | 1303YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on copper substrate | 1303YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 97% area covered | 1304YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 97% area covered | 1304YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 97% area covered | 1304YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 97% area covered | 1304YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 97% area covered | 1304YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 85% area covered | 1305YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 85% area covered | 1305YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 85% area covered | 1305YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 85% area covered | 1305YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 85% area covered | 1305YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/multi-layered (< 10 layers) graphene/copper substrate | 1306YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/multi-layered (< 10 layers) graphene/copper substrate | 1306YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/multi-layered (< 10 layers) graphene/copper substrate | 1306YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/multi-layered (< 10 layers) graphene/copper substrate | 1306YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/multi-layered (< 10 layers) graphene/copper substrate | 1306YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/PVC substrate, > 97% area covered | 1307YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/PVC substrate, > 97% area covered | 1307YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/PVC substrate, > 97% area covered | 1307YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/PVC substrate, > 85% area covered | 1308YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/PVC substrate, > 85% area covered | 1308YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/PVC substrate, > 85% area covered | 1308YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/multi-layered (< 10 layer) graphene/PVC substrate | 1309YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/multi-layered (< 10 layer) graphene/PVC substrate | 1309YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/multi-layered (< 10 layer) graphene/PVC substrate | 1309YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on silicon-oxide substrate, > 97% area covered | 1310YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on silicon-oxide substrate, > 97% area covered | 1310YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on silicon-oxide substrate, > 97% area covered | 1310YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on silicon-oxide substrate, > 97% area covered | 1310YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on silicon-oxide substrate, > 85% area covered | 1311YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on silicon-oxide substrate, > 85% area covered | 1311YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on silicon-oxide substrate, > 85% area covered | 1311YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on silicon-oxide substrate, > 85% area covered | 1311YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on silicon-oxide substrate | 1312YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on silicon-oxide substrate | 1312YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on silicon-oxide substrate | 1312YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on silicon-oxide substrate | 1312YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Single-layered graphene on quartz substrate, > 97% area covered | 1313YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Single-layered graphene on quartz substrate, > 97% area covered | 1313YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Single-layered graphene on quartz substrate, > 97% area covered | 1313YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on quartz substrate, > 85% area covered | 1314YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on quartz substrate, > 85% area covered | 1314YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on quartz substrate, > 85% area covered | 1314YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on quartz substrate | 1315YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on quartz substrate | 1315YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on quartz substrate | 1315YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on PET substrate, > 97% area covered | 1316YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on PET substrate, > 97% area covered | 1316YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on PET substrate, > 97% area covered | 1316YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on PET substrate, > 97% area covered | 1316YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on PET substrate, > 85% area covered | 1317YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on PET substrate, > 85% area covered | 1317YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on PET substrate, > 85% area covered | 1317YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on PET substrate, > 85% area covered | 1317YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on PET substrate | 1318YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on PET substrate | 1318YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on PET substrate | 1318YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on PET substrate | 1318YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Graphene Foam on Nickel Foam (thickness 1-1.2 mm) | 1319YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| Graphene Foam on Nickel Foam (thickness 1-1.2 mm) | 1319YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| Graphene Foam on Nickel Foam (thickness 1-1.2 mm) | 1319YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| Graphene Foam on Nickel Foam (thickness 1-1.2 mm) | 1319YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| Graphene on PVC (nickel foam removed) | 1320YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| Graphene on PVC (nickel foam removed) | 1320YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| Graphene on PVC (nickel foam removed) | 1320YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| Graphene on PVC (nickel foam removed) | 1320YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| Silver Nanopowder (Ag, 99.9+%, 20 nm) 0.1 - 1 wt% Dispersion in Water with Anionic Surfactant | 7031HW | 500ml; 1L; |
| Silver Nanopowder (Ag, 99.9+%, 50 nm) 0.1 - 1 wt% Dispersion in Water with Anionic Surfactant | 7033HW | 500ml; |
| Silver Nanopowder (Ag, 99.9+%, 100 nm) 0.1 - 1 wt% Dispersion in Water with Anionic Surfactant | 7035HW | 500ml; |
| Silver Nanopowder (Ag, 99.9+%, 200 nm) 0.1 - 1 wt% Dispersion in Water with Anionic Surfactant | 7038HW | 500ml; |
| Gold Nanopowder (Au, 99.99%, 20 nm) 0.1 - 1 wt% Dispersion in Water | 7041HW | 500ml; |
| Platinum Nanopowder (Pt, 99.9+%, 20-30nm) 0.1wt% Dispersion in Water | 0488HW | 500ml; |
| Palladium Nanopowder (Pd, 99.99%, 20 nm) 0.1 - 1 wt% Dispersion in Water | 7051HW | 500ml; |
| Palladium Nanopowder (Pd, 99.9+%, 10 nm) 0.1wt% Dispersion in Water | 0466HW | kg; |
| Germanium Nanopowder (Ge, 99.9+%, 400 nm) Dispersed in 850ml of Ethanol | 0388HW | 咨询 |
| Aluminum Oxide (alpha, 20 wt%, 30-60nm) in Water | 7017WJWA | 1kg; |
| Aluminum Oxide (gamma, 20 wt%, 30 nm) in Water | 7017WJWG | 1kg; |
| Aluminum Oxide (gamma, 20 wt%, 10 nm) in water | 7016WJWG | 1kg; |
| CuO, 1 wt%, in water, APS 30 nm | 9019WJ | kg; |
| Silicon Oxide (15 wt%, 30 nm) in water | 7019WJ | 30kg; |
| Silicon Oxide (25 wt%, 30 nm) in water | 7015WJ | 1kg; |
| Silicon Oxide (25 wt%, 30 nm) in water | 7016WJ | 1kg; 10kg; |
| Titanium Oxide (Rutile, 40 wt%, 30-50 nm) in water | 7013WJWR | 1kg; |
| Titanium oxide TiO2 (40wt%, Rutile, 30-50 nm ) in Isopropanol | 5006WJ | kg; |
| Titanium Oxide (TiO2, Rutile, >99.5%, 5-30 nm,15 wt%) in water | 7012WJWR | 1kg; |
| Titanium Oxide (Anatase, 20 wt%, 5-30 nm) in IPA | 7014WJWA | 1kg; |
| Titanium Oxide (Anatase, ATO doped, 20 wt%, 15-25 nm) Slurry | 7030WJ | 5kg; |
| Titanium Oxide (Anatase, 20 wt%, 5-30 nm) in water | 7012WJWA | 1kg; |
| Titanium Oxide (Anatase, 15 wt%, 5-30 nm) in water | 7011WJWA | 1kg; |
| Titanium Oxide (TiO2, Anatase, >99.5%, 15 nm, 15 wt%) in water, negatively charged | 7011WJWANC | 咨询 |
| Titanium Oxide Nanopowder (anatase, 5 wt%, 10-20 nm) in ethanol | 7019HT | 1L; 5L; |
| Zinc Oxide (20 wt%, 40 nm) in water | 7006WJ | 1L |
| Indium Tin Oxide (ITO, 30 wt%, 20-30 nm) in Water | 7026HZW | 100g; |
| Silver nanowires (Dia. 70 - 80 nm, Length > 10 um) | 0475HW6 | 1 g (silver nanowires); 5 g (silver nanowires); |
| Silver nanowires (Dia. 30 - 50 nm, Length > 10 um) | 0475HW5 | 1 g (silver nanowires); 5 g (silver nanowires); |
| Silver Nanowires (Dia. 20 - 30 nm, Length > 10 um) | 0475HW4 | 1 g (silver nanowires); 5 g (silver nanowires); |
| Silver nanowires (D = 14-31 nm, L = 5-40 um, 99.95+%, 1 wt% Ag in ethanol) | 0475NW2E | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 14-31 nm, L = 5-40 um, 99.95+%, 1 wt% Ag in isopropanol) | 0475NW2I | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 14-31 nm, L = 5-40 um, 99.95+%, 1 wt% Ag in water) | 0475NW2W | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 25-35 nm, L = 15-25 um, 99.95+%, 1 wt% Ag in ethanol) | 0475NW3E | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 25-35 nm, L = 15-25 um, 99.95+%, 1 wt% Ag in isopropanol) | 0475NW3I | 1 g (Ag nanowires); 2 g (Ag nanowires); 3 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 25-35 nm, L = 15-25 um, 99.95+%, 1 wt% Ag in water) | 0475NW3W | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 35-45 nm, L = 10-20 um, 99.95+%, 1 wt% Ag in ethanol) | 0475NW5E | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 35-45 nm, L = 10-20 um, 99.95+%, 1 wt% Ag in isopropanol) | 0475NW5I | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 35-45 nm, L = 10-20 um, 99.95+%, 1 wt% Ag in water) | 0475NW5W | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 55-75 nm, L = 20-40 um, 99.95+%, 1 wt% Ag in ethanol) | 0475NW6E | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 55-75 nm, L = 20-40 um, 99.95+%, 1 wt% Ag in isopropanol) | 0475NW6I | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 55-75 nm, L = 20-40 um, 99.95+%, 1 wt% Ag in water) | 0475NW6W | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Single-walled Carbon nanotubes - 60%SWNTs (90%CNTs) | 1283YJ | 1g; 5g; |
| SWNT-OH (90% CNTs, 60% SWNTs) | 1285YJF | 1g; 5g; |
| SWNT-COOH (90% CNTs, 60% SWNTs) | 1287YJF | 1g; 5g; |
| Short SWNTs (90% CNTs, 60% SWNTs) | 1281YJS | 1g; 5g; |
| SWNT-OH (> 60%, OD 1-2 nm, Length 1-3 um) | 1285YJFS | 1g; |
| SWNT-COOH (> 60%, OD 1-2 nm, Length 1-3 um) | 1287YJFS | 1g; |
| High-Purity SWNTs (> 95%, OD < 2 nm, Length 5-30 um) | 1288YJ | g; |
| Single-walled carbon nanotubes - 90%SWNTs (95%CNTs) | 1284YJ | g; 5g; |
| SWNT-OH (95% CNTs, 90% SWNTs) | 1286YJF | 1g; |
| SWNT-COOH (95% CNTs, 90% SWNTs) | 1288YJF | 1g; |
| SWCNTs (> 90%, OD 1-2 nm, Length 1-3 um) | 1246YJS | 1g; 5g; |
| Single-Walled Carbon Nanotubes (90+%), -OH Functionalized | 1586YJF | 1g; |
| Single-Walled Carbon Nanotubes (90+%), -COOH Functionalized | 1588YJF | 1g; |
| High-Purity SWNTs (> 95%, OD < 2 nm, Length 5-30 um) | 1288YJ | 1g; |
| High-Purity SWNTs, -OH functionalized (> 95%, OD 1-2 nm, Length 5-30 um) | 1368YJF | 1g; |
| High-Purity SWNTs, -COOH functionalized (> 95%, OD 1-2 nm, Length 5-30 um) | 1369YJF | 1g; |
| High-Purity Short SWNTs (> 95%, OD 1-2 nm, Length 1-3 um) | 1372YJ | 1g; |
| High-Purity Short SWNTs, -OH Functionalized (> 95%, OD 1-2 nm, Length 1-3 um) | 1373YJF | 1g; |
| High-Purity Short SWNTs, -COOH Functionalized (> 95%, OD 1-2 nm, Length 1-3 um) | 1374YJF | 1g; |
| High-Purity SWNTs (> 95%), -NH2 functionalized | 1370YJF | 1g; 5g; |
| High-Purity Short SWNTs (> 95%), -NH2 functionalized | 1371YJFS | 1g; 5g; |
| High-Purity SWNTs (> 95 %, surface area > 1,075 m2/g) | 1300YJ | 1g; |
| DWNTs (> 60%, OD 2-4 nm, Length ~50 um) | 1280YJD | 1g; 5g; 25g; |
| DWNTs-COOH (> 60%, OD 2-4 nm, Length ~50 um) | 1281YJD | g; |
| Multi-Walled Carbon Nanotube -MWNT (98%, OD 4-6 nm) | 1389YJ | 10g; |
| Multi-wall carbon nanotube -MWNT (98%, OD 5-15 nm) | 1203YJ | 10g; 25g; |
| Multi-walled carbon nanotube -MWNT (99%, OD 5-15 nm) | 8101YJ | 10g; |
| Multi-wall carbon nanotube -MWNT (95+%, OD 8-15 nm) | 1204YJ | 10g; |
| Multi-wall carbon nanotube -MWNT (>98%, OD 10-20 nm) | 1205YJ | 10g; |
| Multi-wall carbon nanotube -MWNT (>98%, OD 20-30 nm) | 1229YJ | 10g; |
| Multi-wall carbon nanotube -MWNT (98+%, OD 30-50 nm) | 1231YJ | 10g; |
| Multi-wall carbon nanotube -MWNT (>98%, OD 30-80 nm) | 1233YJ | 10g; 25g; |
| Short MWNT (98+%, OD 4-6 nm, Length 0.5-2 um) | 1392YJS | 5g; |
| Short MWNT (98+%, OD 5-15 nm, Length 0.5-2 um) | 1225YJS | 5g; |
| Short MWNT (99+%, OD 5-15 nm, Length 0.5-2 um) | 8104YJS | 5g; |
| Short MWNT (95+%, OD 8-15 nm, Length 0.5-2 um) | 1235YJS | 5g; |
| Short MWNT (>98%, OD 10-20 nm, Length 0.5-2 um) | 1236YJS | 10g; |
| Short MWNT (98+%, OD 20-30 nm, Length 0.5-2 um) | 1237YJS | 5g; |
| Short MWNT (98+%, OD 30-50 nm, Length 0.5-2 um) | 1238YJS | 5g; |
| Short MWNT (98+%, OD 30-80 nm, Length 0.5-2 um) | 1227YJS | 5g; |
| Graphitized MWNT (99.9%, OD 8-15 nm) | 1219YJ | 10g; 25g; |
| Graphitized MWNT (99.9%, OD 10-20 nm) | 1220YJ | 10g; |
| Graphitized MWNT (99.9%, OD 20-30 nm) | 1221YJ | 5g; |
| Graphitized MWNT (99.9%, OD 30-50 nm) | 1222YJ | 5g; |
| Graphitized MWNT (99.9%, OD 30-80 nm) | 1223YJ | 5g; |
| Industrial-grade MWNT (95+%, OD 4-6 nm) | 1395YJ | 1kg; |
| Industrial-Grade MWNT (95+%, OD 5-15 nm) | 1201YJG | 1kg; |
| Industrial-grade MWNT (95%, OD 8-15 nm) | 1201YJA | 1kg; |
| Industrial-grade MWNT (95+%, OD 10-20 nm) | 1201YJB | 1kg; |
| Industrial-grade MWNT (95+%, OD 10-30 nm) | 1201YJC | 1kg; |
| Industrial-grade MWNT (95+%, OD 20-40 nm) | 1201YJD | 1kg; |
| Industrial-Grade MWNT (95+%, OD 30-80 nm) | 1201YJE | 1kg; |
| MWNT-OH (98+%, OD 4-6 nm) | 1390YJF | 10g; |
| MWNT-OH (98+%, OD 5-15 nm) | 1261YJF | 5g; |
| MWNT-OH (99+%, OD 5-15 nm) | 8103YJF | 5g; |
| MWNT-OH (95+%, OD 8-15 nm) | 1262YJF | 5g; |
| MWNT-OH (98+%, OD 10-20 nm) | 1263YJF | 5g; |
| MWNT-OH (98+%, OD 20-30 nm) | 1264YJF | 5g; 25g; 100g; |
| MWNT-OH (98+%, OD 30-50 nm) | 1265YJF | 5g; |
| MWNT-OH (98+%, OD 30-80 nm) | 1266YJF | 5g; |
| Short MWNT-OH (98+%, OD 4-6 nm, Length 0.5-2 um) | 1393YJF | 5 g; 100 g; |
| Short MWNT-OH (98+%, OD 5-15 nm, Length 0.5-2 um) | 1247YJF | 5g; |
| Short MWNT-OH (99+%, OD 5-15 nm, Length 0.5-2 um) | 8106YJF | 5g; |
| Short MWNT-OH (95+%, OD 8-15 nm, Length 0.5-2 um) | 1248YJF | 5g; |
| Short MWNT-OH (98+%, OD 10-20 nm, Length 0.5-2 um) | 1249YJF | 5g; |
| Short MWNT-OH (98+%, OD 20-30 nm, Length 0.5-2 um) | 1251YJF | 5g; |
| Short MWNT-OH (98+%, OD 30-50 nm, Length 0.5-2 um) | 1252YJF | 5g; |
| Short MWNT-OH (98+%, OD 30-80 nm, Length 0.5-2 um) | 1253YJF | 1g; 5g; |
| Graphitized MWNT-OH (99.9%, OD 8-15 nm) | 1224YJF | 1g; |
| Graphitized MWNT-OH (99.9%, OD 10-20 nm) | 1228YJF | 1g; 5g; |
| Graphitized MWNT-OH (99.9%, OD 20-30 nm) | 1235YJF | 1g; 5g; |
| Graphitized MWNT-OH (99.9%, OD 30-50 nm) | 1239YJF | 1g; 5g; |
| Graphitized MWNT-OH (99.9%, OD 30-80 nm) | 1240YJF | 1g; 5g; |
| Industrial-grade MWNT-OH (95+%, OD 5-15 nm) | 1201YJI | 1kg; |
| Industrial-grade MWNT-OH (95+%, OD 8-15 nm) | 1201YJL | 1kg; |
| Industrial-grade MWNT-OH (95+%, OD 10-30 nm) | 1207YJF | 1kg; |
| Industrial-grade MWNT-OH (95+%, OD 20-40 nm) | 1208YJF | 1kg; |
| Industrial-grade MWNT-OH (95+%, OD 30-80 nm) | 1209YJF | 1kg; |
| MWNT-COOH (98+%, OD 4-6 nm) | 1391YJF | 10g; |
| MWNT-COOH (98+%, OD 5-15 nm) | 1267YJF | 5g; |
| MWNT-COOH (99+%, OD 5-15 nm) | 8102YJF | 10g; |
| MWNT-COOH (95+%, OD 8-15 nm) | 1268YJF | 5g; |
| MWNT-COOH (98+%, OD 10-20 nm) | 1269YJF | 5g; |
| MWNT-COOH (98+%, OD 20-30 nm) | 1270YJF | 5g; |
| MWNT-COOH (98+%, OD 30-50 nm) | 1271YJF | 5g; |
| MWNT-COOH (98+%, OD 30-80 nm) | 1272YJF | 5g; |
| Short MWNT-COOH (98+%, OD 4-6 nm, Length 0.5-2 um) | 1394YJF | 5g; |
| Short MWNT-COOH (98+%, OD 5-15 nm, Length 0.5-2 um) | 1254YJF | 5g; |
| Short MWNT-COOH (99+%, OD 5-15 nm, Length 0.5-2 um) | 8105YJF | 5g; |
| Short MWNT-COOH (95+%, OD 8-15 nm, Length 0.5-2 um) | 1255YJF | 1g; 5g; |
| Short MWNT-COOH (98+%, OD 10-20 nm, Length 0.5-2 um) | 1256YJF | 5g; |
| Short MWNT-COOH (98+%, OD 20-30 nm, Length 0.5-2 um) | 1257YJF | 1g; 5g; |
| Short MWNT-COOH (98+%, OD 30-50 nm, Length 0.5-2 um) | 1259YJF | 1g; 5g; |
| Short MWNT-COOH (98+%, OD 30-80 nm, Length 0.5-2 um) | 1273YJF | 1g; 5g; |
| Graphitized MWNT-COOH (99.9%, OD 8-15 nm) | 1241YJF | 10g; |
| Graphitized MWNT-COOH (99.9%, OD 10-20 nm) | 1242YJF | 10g; |
| Graphitized MWNT-COOH (99.9%, OD 20-30 nm) | 1243YJF | 10g; |
| Graphitized MWNT-COOH (99.9%, OD 30-50 nm) | 1244YJF | 1g; 5g; |
| Graphitized MWNT-COOH (99.9%, OD 30-80 nm) | 1245YJF | 1g; 5g; |
| Industrial-grade MWNT-COOH (95+%, OD 5-15 nm) | 1201YJH | 1kg; |
| Industrial-grade MWNT-COOH (95+%, OD 8-15 nm) | 1201YJK | 1kg; |
| Industrial-grade MWNT-COOH (95+%, OD 10-30 nm) | 1210YJF | 1kg; |
| Industrial-grade MWNT-COOH (95+%, OD 20-40 nm) | 1216YJF | 1kg; |
| Industrial-grade MWNT-COOH (95+%, OD 30-80 nm) | 1218YJF | 1kg; |
| Aligned MWNT (98+%, OD 8-15 nm, Length: 30-50 um) | 1215YJA | 25g; |
| Carbon nanofibers (70+%, D = 200-600 nm, L = 5-50 um) | 1177YJ | 10g; |
| Carbon Nanofibers (95+%, D = 50-200 nm, L = 1-15 um) | 8107YJ | 10g; |
| Graphitized carbon nanofibers (95+%, OD = 50-200 nm, L = 1-15 um) | 1178YJ | 10g; |
| Graphene (> 98 wt%, D > 50 um, < 3 layers) | 2191YJ | 1g; 5g; |
| Graphene Oxide (> 99 wt%, D 0.5-3 um, < 3 Layers) | 2192YJ | 1g; 5g; |
| Graphene Nanoplatelets (> 99.5 wt%, D 5-10 um, < 20 layers) | 8056YJ | 1g; 5g; 25g; |
| Industrial-Grade Graphene Nanoplatelets (> 90 wt%, D 2-16 um, < 30 layers) | 8055YJ | 50g; 250g; 1kg; |
| *60% Ni/38% MWNT (95+%, OD 8-15 nm) | 1293YJ | 10g; |
| *60% Ni/38% MWNT (95+%, OD 10-20 nm) | 1294YJ | 10g; |
| *60% Ni/38% MWNT (95+%, OD 20-30 nm) | 1295YJ | 10g; |
| *60% Ni/38% MWNT (95+%, OD 30-50 nm) | 1296YJ | 10g; |
| *60% Ni/38% MWNT (95+%, OD 30-80 nm) | 1297YJ | 10g; |
| MWNT-NH2 (95+%, OD 8-15 nm, 0.45 wt% amino) | 1562YJF | 5g; |
| Nitrogen-doped MWNTs (98%, OD 30-80 nm) | 8054YJ | 5g; |
| Large inner diameter thin-walled multi-walled carbon nanotubes | 1563YJF | 5g; |
| Coiled CNTs (60+%, OD 100-200 nm, Length 1-10 um) | 1298YJ | 5g; |
| Silver Nanopowder (Ag, 99.99%, 400 nm ) | 0487HW | 咨询 |
| Silver Nanopowder (Ag, 99.9%, 200 nm ) | 0479HW | 咨询 |
| Silver Nanopowder (Ag, 99.99%, 100 nm ) | 0489HW | 咨询 |
| Silver Nanopowder (Ag, 99%, 90-210 nm) | 0471CD | 咨询 |
| Silver Nanopowder (Ag, 99.9%, 80 nm ) | 0475HW | 咨询 |
| Silver Nanopowder (Ag, 99.9%, 80 nm, w/~0.3% PVP ) | 0476HW | 咨询 |
| Silver Nanopowder (Ag, 99.9% , 40 nm ) | 0473HW | 咨询 |
| Silver Nanopowder (Ag, 99.9%, 40 nm, w/~0.3% PVP ) | 0474HW | 咨询 |
| Silver Nanopowder (Ag, 99.9%, 30-50 nm, w/0.2 wt% PVP) | 0477YD | 咨询 |
| Silver Nanopowder (Ag, 35 nm, 99.5%, metal basis) | 0476JY | 咨询 |
| Silver Nanopowder (Ag, 99.9% , 20 nm ) | 0477HW | 咨询 |
| Silver Nanopowder (Ag, 99.9%, 20 nm, w/~0.3% PVP ) | 0478HW | 咨询 |
| Aluminum Powder (99.9%, 500 um) | 0156HW | 咨询 |
| Aluminum Powder (99.9%, 50 um) | 0154HW | 咨询 |
| Aluminum Powder (99.9%, 5 um) | 0152HW | 咨询 |
| Aluminum Nanoparticles (99.9%, 500 nm) | 0150HW | 咨询 |
| Aluminum Nanopowder (Al, 99.9+%, 70-80 nm) | 0137HW | 咨询 |
| Aluminum Nanopowder (99.9+%, 70-80 nm, w/PVP) | 0140HW | 咨询 |
| Aluminum Nanopowder (Al, 99.9+%, 40-50 nm) | 0138HW | 咨询 |
| Aluminum Nanopowder (99.9+%, 40-50 nm, w/PVP) | 0139HW | 咨询 |
| Aluminum Nanopowder (Al, 99+%, metal basis, 18 nm) | 0136JY | 咨询 |
| Gold (Au) Nanopowder (99.9%, 50-100 nm) | 0795CD | 咨询 |
| Gold (Au) Nanopowder (25nm, 99.9%) | 8801HW | 咨询 |
| Gold (Au) Nanopowder (10-20 nm, 99.95%) | 8796HW | 咨询 |
| Gold (Au) Nanopowder (10nm, 99.9%) | 8799HW | 咨询 |
| Bismuth Nanopowder (Bi, 99.9%, 80-100 nm) | 0832HW | 咨询 |
| Bismuth Nanopowder (Bi, 99.5%, 40-60 nm) | 0831HW | 咨询 |
| Nano Activated Carbon (C, 88+%, 100 nm) | 1211NH | 咨询 |
| Diamond Nanopowder (synthesized, 55-70%, 4-15nm) | 1311JGY | 咨询 |
| Diamond Nanopowder (synthesized, 98+%, 3-10 nm) | 1321JGY | 咨询 |
| Diamond Nanopowder (synthesized, 97%, 3-6 nm) | 1350SL | 咨询 |
| Graphite Nanopowder (400 nm, 99.9%) | 1250HT | 咨询 |
| *Cobalt Nanopowder, Carbon Coated (Co, 99%, 40 nm) | 0286HW | 咨询 |
| *Cobalt Nanopowder (Passivated, 99.8%, 28 nm) | 0276JY | 咨询 |
| *Chromium Nanopowder (Cr, 99.5%, 50 nm) | 0240XX | 咨询 |
| *Copper Nanopowder (Cu, 99%, 500 nm) | 0293HW | 100g; |
| *Copper Nanopowder (Cu, 99.9%, 200 nm) | 0290HW | 25g; |
| *Copper Nanopowder (Cu, 99.9%, 100 nm) | 0298HW | 25g; |
| *Copper Nanopowder (Partially Passivated, 99+%, 80 nm) | 0294HW | 25g; |
| *Copper Nanopowder (Cu, 99.9%, 70 nm) | 0291HW | 25g; |
| *Copper Nanopowder (Cu, 99.5%, 50-80 nm) | 0292HW | 25g; |
| *Copper Nanopowder (Cu, 99.9%, 40 nm) | 0295HW | 25g; |
| *Copper Nanopowder (Cu, carbon coated, 99.8%, 25 nm) | 0297JY | 5g; |
| *Iron Nanopowder (Fe, 99.9%, 500nm) | 0272YM | 100g; 1kg; |
| *Iron Nanopowder (Fe, 99.9%, 100 nm) | 0264HW | 25g; |
| *Iron Nanopowder (Fe, 99.9%, 70 nm) | 0263HW | 25g; 100g; |
| *Iron Nanopowder (Fe, 99.9%, 40 nm) | 0262HW | 25g; 100g; |
| *Iron nanopowder, carbon coated (Fe/C, 99.6%, 25 nm) | 0267JY | 25g; |
| Germanium Nanopowder (Ge, 99.9+%, 600 nm) | 0327HW | 25g; |
| Germanium Nanopowder (Ge, 99.9%, 500 nm) | 0331HW | 1kg; |
| Germanium Nanopowder (Ge, 99.9+%, 400 nm) | 0326HW | 1kg; |
| Germanium Nanopowder (Ge, 99.9+%, 300 nm) | 0325HW | 1kg; |
| Germanium Nanopowder (Ge, 99.9+%, 200 nm) | 0323HW | 100g; kg; |
| Germanium Nanopowder (Ge, 99.9+%, 150 nm) | 0322HW | 咨询 |
| Germanium Nanopowder (Ge, 99.9+%, < 100 nm) | 0322HH | 咨询 |
| Germanium Nanopowder (Ge, 99.9+%, 20-50 nm) | 0321HW | 5g; |
| Iridium Nanopowder (Ir, 99.95%, 20-30 nm), wet powder in Deionized Water | 0771HW | 咨询 |
| *Molybdenum Nanopowder (Mo, 99.5%, 70 nm) | 0423HW | 咨询 |
| Niobium Nanopowder (Nb, 99.9%, 40-60 nm) | 0411HW | 咨询 |
| *Nickel Nanopowder (Ni, 99%, 800 nm) | 0302HW | 咨询 |
| *Nickel Nanopowder (Ni, 99%, 400 nm) | 0301HW | 100g; 1kg; |
| *Nickel Nanopowder (Ni, 99+%, 300 nm) | 0289HW | 1kg; |
| *Nickel Nanopowder (Ni, 99.5%, 100 nm) | 0285HW | 25g; |
| *Nickel Nanopowder (Ni, 99.9%, 80 nm) | 0284HW | 300g; |
| *Nickel Nanopowder (Ni, 99.5%, 70 nm) | 0288HW | 25g; |
| *Nickel Nanopowder (Ni, 99.5%, 40 nm) | 0283HW | 25g; |
| *Nickel Nanopowder, carbon coated (Ni/C, 99.9%, 20 nm) | 0287JY | 5g; |
| Palladium Nanopowder (Pd, 99.95%, 20-30 nm) | 0462HW | 咨询 |
| Platinum Nanopowder (Pt, 99.95%, 20-30 nm) | 0782HW | 咨询 |
| Platinum Nanopowder, PVP coated (Pt, 99.95%, 20-30 nm) | 0787HW | 1g; |
| Platinum Nanopowder (Pt, 99.9%, 20-30 nm) | 0786HW | 1g; 5g; |
| Rhodium Nanopowder (Rh, 99.95%, 20-30 nm) | 0451HW | 咨询 |
| Ruthenium Nanopowder (Ru, 99.95%, 20-30 nm) | 0441HW | 1g; |
| *Silicon Nanopowder (Si, 99%, 400 nm) | 0144HW | 100g; |
| *Silicon Nanopowder (Si, 99.9%, 100 nm) | 0149HW | 100g; |
| *Silicon Nanopowder (Si, > 97%, 50 nm) | 0145KE | 咨询 |
| *Silicon Nanopowder (Si, 99%, 30-50 nm) | 0147HW | 50g; |
| *Silicon Nanopowder (Si, 98+%, 30-50 nm) | 0141JS | 50g; 100g; 500g; 1kg; |
| Tin Nanopowder (Sn, 70 nm, w/PVP ) | 5522HW | 500g; |
| Tin Nanopowder (Sn, 99.9%, 60-80 nm) | 0501HW | 咨询 |
| *Tantalum Nanopowder (Ta, 99.9%, 40 nm) | 0225HW | 25g; |
| *Tantalum Nanopowder (Ta, 99.9%, 70 nm) | 0224HW | 25g; |
| *Titanium Nanopowder (Ti, 99%, 60-80 nm) | 0227HW | 25g / $361; |
| *Tungsten Powder (W, 99.5+%, 1-2 um) | 0747HW | 100g; |
| *Tungsten Nanopowder (W, 99.5%, 500 nm) | 0749HW | 1kg; |
| *Tungsten Nanopowder (W, 99.5%, <100 nm) | 0745HW | 100g; |
| *Zinc Nanopowder (Zn, 99%, 500 nm) | 0318HW | 1kg; |
| *Zinc Nanopowder (Zn, 99.5%, 130 nm) | 0303HW | 25g; |
| *Zinc Nanopowder (Zn, 99.9+%, 100 nm) | 0306JY | 25g; |
| *Zinc Nanopowder (Zn, 99.5%, 80 nm) | 0304HW | 25g; |
| *Aluminum Nitride Nanopowder (AlN, Amorphous, <0.5um, 99.9%) | 1004HW | 咨询 |
| Aluminum Nitride Nanopowder (AlN, 99.9 %, 0.5 um) | 1005HW | 咨询 |
| *Aluminum Nitride Nanopowder (AlN, 99.5 %, 70-80 nm) | 1002HW | 咨询 |
| Boron Carbide Powder (B4C, 99%, 500 μm) | 1175HW | 咨询 |
| Boron Carbide Powder (B4C, 99%, 50 μm) | 1177HW | 咨询 |
| Boron Carbide Powder (B4C, 99%, 40 μm) | 1179HW | 1kg; |
| Boron Carbide Powder (B4C, 98%, 20μm) | 1172HW | 1kg; |
| Boron Carbide Powder (B4C, 98%, 10μm) | 1169HW | 1kg; |
| Boron Carbide Powder (B4C, 99%, 5 μm) | 1165HW | 1kg; |
| Boron Carbide Powder (B4C, 99%, 2 um) | 1183HW | 1 kg; |
| Boron Carbide Powder (B4C, 99+%, 1-2 μm) | 1162HW | 咨询 |
| Boron Carbide Nanopowder (B4C, 99+%, 500 nm) | 1160HW | 500g; |
| Boron Carbide Nanopowder (B4C, 99%, 50nm) | 1161HY | 100g; |
| Boron Nitride Powder (BN, hexagonal, 99.8%, 0.6-1.2um) | 1182HW | 咨询 |
| Boron Nitride Nanopowder (BN, hexagonal, 99%, 137 nm) | 1180YL | 25g; |
| Boron Nitride Nanoplates (BN, 99.5+%, 100 nm) | 1183NJ | 100g; |
| Chromium Carbide Nanopowder (Cr3C2, 99.9%, <100 nm) | 0247HW | 500g; 1kg; |
| Hafnium Boride Nanopowder (HfB2, 99+%, 60 nm) | 1010JC | 100g; |
| Hafnium Carbide Nanopowder (HfC, 99+%, 200 nm) | 1005JC | 500g; |
| Hafnium Carbide Nanopowder (HfC, 99+%, 60 nm) | 1006JC | 100g; |
| Hafnium Carbide Nanopowder (HfC, 99%, 50nm) | 1022JC | kg; |
| Niobium Carbide Nanopowder (NbC, 99.9%, 500 nm) | 3860YM | 咨询 |
| Silicon Carbide Powder (SiC, 500 um, 99%, Hexagonal) | 4652HW | 1kg; ; |
| Silicon Carbide Powder (SiC, 50 um, 99%, Hexagonal) | 4654HW | 1kg; ; |
| Silicon Carbide Micron Powder (SiC, Beta, 40um, 99+%) | 4645HW | 1kg; ; |
| Silicon Carbide Powder (SiC, Beta, 20um, 99+%) | 4643HW | 1kg; ; |
| Silicon Carbide Powder (SiC, Beta, 10um, 99+%) | 4641HW | 1kg; ; |
| Silicon Carbide Micron Powder (SiC, Beta, 7um, 99+%) | 4639HW | 100g; 1kg; ; |
| Silicon Carbide Powder (SiC, beta, 99.8%, 5 μm) | 4637HW | 100g; ; |
| Silicon Carbide Powder (SiC, beta, 99+%, 2 μm) | 4635HW | 咨询 |
| Silicon Carbide Powder (SiC, alpha, 99.9%, 2um) | 4627HY | 1kg; |
| Silicon Carbide Powder (SiC, 500 nm, 99%, Cubic) | 4656HW | 1kg; ; |
| Silicon Carbide Nanopowder (SiC, beta, 99%, 80-100 nm) | Stock # 4629HW | 100g; |
| Silicon Carbide Nanopowder (SiC, alpha, 99.9%, 55 nm) | 4625HY | 100g; |
| Silicon Carbide Nanopowder (SiC, beta, 97.5%, 45-55 nm) | 4620KE | 200g; |
| Silicon Carbide Nanopowder (SiC, alpha, 99.9%, 30 nm) | 4626HY | 100 g; 150 g; |
| Silicon Carbide Nanowhisker (beta, SiC, 99+%) | 4622HW | 25g; |
| Silicon Nitride Nanopowder (Si3N4, amorphous, 98.5+%, 15-30 nm) | 4750KE | 100g; |
| Titanium Boride Powder (TiB2, 2-12 μm ) | 5180HW | 100g |
| *Titanium Carbide Powder (TiC, 1 micron, 99%) | 5218YL | 500g; |
| *Titanium Carbide Nanoparticles (TiC, 100-200nm, 99+%) | 5217HW | 1kg; |
| Titanium Carbide (TiC, 99+%, 100 nm) | 5217JC | 100g; |
| *Titanium Carbide (TiC, 98+%, 80 nm) | 5220HT | 25g; 100g; |
| *Titanium Carbide Nanopowder (TiC, 97+%, 50 nm) | 5216KE | 100g; |
| *Titanium Nitride Powder (TiN, 99%, 1-3um) | 5352JC | 500g; 1kg; |
| *Titanium Nitride Nanoparticles (TiN, 99%, 100-200 nm) | 5357HW | 500g; |
| *Titanium Nitride Nanopowder (TiN, 97+%, 20 nm) | 5350KE | 100g; |
| Tungsten Carbide/Cobalt Nanopowder (8wt%Co/WC, < 200 nm, 99.5%) | 5561HW | 100g |
| Zirconium Carbide Nanopowder (ZrC, 99%, 8 um) | 5905KE | 100g; 250g; 500g; |
| *Zirconium Carbide Nanopowder (ZrC, 97%, 60 nm) | 5901KE | 100g; |
| *Zirconium Nitride Nanopowder (ZrN, 99.5%, 1-3um) | 6101JC | 500g; kg; |
| Zirconium Boride Nanopowder (ZrB2, 99%, 60 nm) | 5950JC | 100g; |
| Aluminum Oxide (Al2O3) Nanopowder (alpha, 99.9+%, 500 nm) | 1037HT | 100g; |
| Aluminum Oxide (Al2O3) Nanopowder (alpha, 99+%, 500 nm) | 1038HT | 100g; |
| Aluminum Oxide Nanopowder (alpha, aluminate coated, 98+%, 500 nm) | 1039HT | 100g; |
| Aluminum Oxide (Al2O3) Nanopowder (alpha, 99.9%, 200 nm) | Stock #:1040LQS | 100g |
| Aluminum Oxide (Al2O3) Nanopowder (alpha, 99.9%, 150 nm) | 1005MR | 100g ; |
| Aluminum Oxide (Al2O3) Nanopowder (alpha, 99.9+%, 40-50 nm) | 1044HT | 100g; |
| Aluminum Oxide (Al2O3) Nanopowder (alpha/theta, 99.99%, ~30nm ) | 1018WJ | 100g ; |
| Aluminum Oxide (Al2O3) Nanopowder (gamma, 99+%, 500 nm) | 1045HT | 100g; |
| Aluminum Oxide (Al2O3) Nanopowder (gamma, 99.97%, 20-30 nm) | 1020MR | 100g; 500g; 1kg; |
| Aluminum Oxide Nanopowder (gamma, 99.5%, 50 nm) | 1007XX | 咨询 |
| Aluminum Oxide (Al2O3) Nanopowder (gamma, 99.99%, 10 nm) | 1043HT | 100g; |
| Aluminum oxide nanopowder, (γ-phase) APS 20-30 nm, 99.95+% | 0125HW | 咨询 |
| Aluminum Oxide Nanopowder ( 99.99%, 30 nm ) for Lithium Batteries | 1016WJ | 咨询 |
| Aluminum Hydroxide Nanopowder (99.5 %, 50 nm) | 1040WJ | 咨询 |
| Boron Oxide Nanopowder (B2O3, 98%, 40-80 nm) | 1185DF | 咨询 |
| Boron Oxide Nanopowder (B2O3, 99%, 40-80 nm) | 1186DF | 1kg; |
| Bismuth Oxide Nanopowder (Bi2O3 , 99.9%, 100 nm) | 1171HT | kg; |
| Cerium Oxide, (CeO2, 99.99%, 200 nm) | 1445MG | 100g; |
| Cerium Oxide Nanopowder (CeO2, 99%, 50-100 nm) | 1408HW | 100g; |
| Cerium Oxide (CeO2, 99.99%, 20-30 nm) | 1444ZQ | 100g; |
| Cerium Oxide Nanopowder (CeO2, 99.9%, 15-30 nm) | 1406RE | 100g; |
| Cobalt(II,III) Oxide Nanopowder (Co3O4, 99%, 50-80 nm) | 1720HT | 咨询 |
| Chromium Oxide Powder (Cr2O3, 99.8%, 1 um) | 1920FY | 25g; 1kg; |
| Chromium Oxide Powder (Cr2O3, 99.9%, 100 nm) | 1925FY | 100g; 1kg; |
| Chromium Oxide Nanopowder (Cr2O3, 99+%, 60 nm) | 1910FY | 25g; |
| Copper(II) Oxide Nanopowder (CuO, 99+%, 30-50 nm) | 2110FY | 咨询 |
| Copper(I) Oxide Nanopowder (Cu2O, 99%, 30-50 nm) | 2113HW | 25g; 100g; 500g; 1kg; |
| Dysprosium Oxide Nanopowder (Dy2O3, 99.9%, 55 nm) | 2252YS | 25g; |
| Dysprosium Oxide Nanopowder (Dy2O3, 99.9%, 30-70 nm) | 2253ZQ | 25g; |
| Erbium Oxide Nanopowder (Er2O3, 99.9%, 43 nm) | 2310ZQ | 65g; |
| Erbium Oxide Nanopowder (Er2O3, 99.9%, 41-53 nm) | 2350YS | 25g; |
| Erbium Oxide Nanopowder (Er2O3, 99.9%, 20-30 nm) | 2330RE | 25g ; |
| Europium Oxide Nanopowder (Eu2O3, 99.995%, 58 nm) | 2410ZQ | 5g; |
| Europium Oxide Nanopowder (Eu2O3, 99.99%, 45-58 nm) | 2450YS | 5g; |
| Europium Oxide Nanopowder (Eu2O3, 99.99%, 30-50 nm) | 2411RE | 5g; |
| Iron(III) Oxide Nanopowder (Fe2O3, gamma, 99.98%, 50 nm) | 2527YM | 1kg |
| Iron(III) Oxide Nanopowder (Fe2O3, alpha, 99%, 30-50 nm) | 2520ZH | 25g; 100g; |
| Iron(III) Oxide Nanopowder (Fe2O3, alpha, 99%, 30 nm) | 2525WJ | 100g; |
| Iron(II,III) Oxide Nanopowder (Fe3O4, 99%, 100-200 nm) | 2653HW | 100g; |
| Iron(II,III) Oxide Nanopowder (Fe3O4, 97%, 50-100 nm) | 2650TS | 100g; |
| Iron(II,III) Oxide Nanopowder (Fe3O4, 99%, SSA: 9-14 m2/g, 50-100 nm) | 2655HW | 100g; 500g; 1kg; |
| Iron(II,III) Oxide Nanopowder (Fe3O4, 99%, 30 nm) | 2651WJ | 100g; |
| Iron Oxide Nanopowder (Fe3O4, PVP coated, 99+%, 20-30 nm) | 2657HW | 100g; 1kg; |
| Gadolinium Oxide Nanopowder (Gd2O3, 99.9+%, 20-80 nm) | 2680ZQ | 咨询 |
| Gadolinium Oxide Nanopowder (Gd2O3, 99.9%, 15-30 nm) | 2681RE | 咨询 |
| Hafnium Oxide Powder (HfO2, 99.99%, 48um) | 1045HW | 咨询 |
| Hafnium Oxide Powder (HfO2, 99%, 45um) | 1042HW | 咨询 |
| Indium Oxide Nanopowder (In2O3, 99.99%, 100-200 nm) | 2711TN | 咨询 |
| Indium Hydroxide Nanopowder (In(OH)3, 99.99%, 20-70 nm) | 2810TN | 咨询 |
| Lanthanum Oxide Nanopowder (La2O3, 99%, 50 nm) | 2922RE | 咨询 |
| Lanthanum Oxide Nanopowder (La2O3, 99.99%, 15-30 nm) | 2920RE | 咨询 |
| Magnesium Oxide Nanopowder (MgO, 99+%, 40-60 nm) | 3305HT | 咨询 |
| Neodymium Oxide Nanopowder (Nd2O3, 99.9%, 40nm) | 3912RE | 1kg; |
| Magnesium Oxide Nanopowder (MgO, 99+%, 40 nm) | 3304HT | 咨询 |
| Magnesium Hydroxide Nanopowder (Mg(OH)2, 98+%, 100 nm) | 3321HT | 咨询 |
| Molybdenum(VI) Oxide Nanopowder (MoO3 , 99.5%, 100 nm) | 3851XW | 咨询 |
| Neodymium Oxide Nanopowder (Nd2O3, 99.9+%, 83 nm) | 3910ZQ | 咨询 |
| Neodymium Oxide Nanopowder (Nd2O3, 99.9%, 49-64 nm) | 3950YS | 咨询 |
| Neodymium Oxide Nanopowder (Nd2O3, 99.9%, 40nm) | 3912RE | 咨询 |
| Neodymium Oxide Nanopowder (Nd2O3, 99.9%, 15-30 nm) | 3911RE | 25g; |
| Nickel Oxide Nanopowder (Ni2O3, 99.9%, 20-30 nm) | 4216HW | 100g; |
| Praseodymium Oxide Nanopowder (Pr6O11, 99.9%, 15-30 nm) | 4451RE | 25g; |
| Antimony Oxide Nanoparticles (Sb2O3, 99.99%, 20-30nm) | 6850HW | 咨询 |
| Silicon Oxide Powder (SiO2 , quartz, 99.99%, 1-3.5 μm) | 4856WG | 咨询 |
| Silicon Oxide Powder (SiO2 , quartz, 99.998%, 1-3.5um) | 4855WG | 咨询 |
| Silicon Oxide Nanopowder (SiO2 , 99+%, 20 nm) | 4830HT | 咨询 |
| Silicon Oxide Nanopowder (99+%, 20 nm, hydrophilic & lipophilic) | 4831HT | 咨询 |
| Silicon Oxide Nanopowder (99+%, 20 nm, hydrophilic & lipophilic) | 4832HT | 咨询 |
| Silicon Oxide Nanopowder (99+%, 20 nm, hydrophilic & lipophilic) | 4833HT | 咨询 |
| Samarium Oxide Nanopowder (Sm2O3, 99.9%, 42-55 nm) | 4950YS | 咨询 |
| Samarium Oxide Nanopowder (Sm2O3, 99.9%, 15-30 nm) | 4951RE | 咨询 |
| Titanium Oxide Nanopowder (TiO2, amorphous/anatase, 99+%, 5 nm) | 5416HT | 咨询 |
| Titanium Oxide Nanopowder (TiO2, anatase, 99%, 10-30 nm) | 5420HT | 咨询 |
| Titanium Oxide Nanopowder(TiO2, anatase, 99%,15 nm) | 5430MR | 咨询 |
| Titanium Oxide Nanopowder (TiO2, anatase, 99+%, 10 nm) | 5417HT | 咨询 |
| Titanium Oxide Nanopowder (tungsten oxide doped, TiO2/WO3, anatase, 10 nm) | 5418HT | 咨询 |
| Titanium Oxide Nanopowder (TiO2, anatase, 5 nm) | 5421ZH | 咨询 |
| Titanium Oxide Nanotubes (TiO2, anatase, 99%, 10-15 nm) | 5432HW | 咨询 |
| Titanium Oxide Nanopowder (TiO2, anatase/rutile, 99+%, 20 nm) | 5419HT | 咨询 |
| Titanium oxide, silica & alumina coated (anatase/rutile, 30 nm) | 5426HT | 咨询 |
| Titanium oxide (silica, alumina & stearic acid coated, anatase/rutile, 30 nm) | 5427HT | 咨询 |
| Titanium Oxide Nanopowder (silica, alumina & silicone oil coated, anatase/rutile, 30 nm) | 5428HT | 咨询 |
| Titanium oxide, silica coated (anatase/rutile, 20 nm) | 5422HT | 咨询 |
| Titanium oxide, silica & alumina coated (anatase/rutile, 20 nm) | 5423HT | 咨询 |
| Titanium oxide, silica & stearic acid coated (anatase/rutile, 20 nm) | 5424HT | 咨询 |
| Titanium oxide, silica & silicone oil coated (anatase/rutile, 20 nm) | 5425HT | 咨询 |
| Titanium Oxide Nanopowder (TiO2, rutile, 99.9+%, 500 nm) | 5429HT | 咨询 |
| Titanium Oxide Nanopowder (TiO2, rutile, 99.9+%, 150 nm) | 5430HT | 咨询 |
| Titanium Oxide Nanopowder (TiO2, rutile, 99.9+%, 100 nm) | 5431HT | 咨询 |
| Titanium Oxide Nanopowder (TiO2, rutile, 99.8%, 60 nm) | 5486WJ | 咨询 |
| Titanium Oxide Nanopowder (TiO2, rutile, 99.8%, 20-50 nm) | 5484WJ | 咨询 |
| Titanium Oxide (TiO2, rutile, coated with silicon oxide, 20 nm) | 0302HT | 咨询 |
| Titanium Oxide (TiO2, rutile, coated with silicon oxide, 20 nm) | 0301HT | 咨询 |
| Vanadium Oxide Nanopowder (VO2, 99.9+%, 100 - 200 nm) | 5495HW | 咨询 |
| 1.5% Tungsten-doped Vanadium Oxide Nanopowder (W-doped VO2, 99.9+%, 30 - 50 nm) | 5499HW | 咨询 |
| 1% Tungsten-doped Vanadium Oxide Nanopowder (W-doped VO2, 99.9+%, 30 - 50 nm) | 5498HW | 咨询 |
| Tungsten Oxide Nanopowder (WO3, 99.5%, 60-120 nm) | 5508YL | 咨询 |
| Tungsten Oxide Nanopowder (WO3, 99.9+%, 40-50 nm) | 5506BD | 咨询 |
| Tungsten Oxide Nanopowder (WO3, 99+%, 30-70 nm) | 5505YL | 咨询 |
| Tungsten Oxide Nanopowder (WO3, 99+%, 30-70 nm, PVP-coated) | 5506YL | 咨询 |
| Yttrium Oxide Nanopowder (Y2O3, 99.995%, 50-70 nm) | 5610ZQ | 咨询 |
| Yttrium Oxide Nanopowder (Y2O3, 99.99%, 20-40 nm) | 5611RE | 咨询 |
| Yttrium Oxide Nanopowder (Y2O3, 99.9%, 32-36 nm) | 5650YS | 咨询 |
| Yttrium Oxide Nanopowder (Y2O3, 99.995%, 20-40 nm) | 5611ZQ | 咨询 |
| Ytterbium Oxide Nanopowder (Yb2O3, 10-80 nm, 99.9%) | 5671RE | 咨询 |
| Zinc Oxide Nanopowder (ZnO, 99+%, 800 nm) | 5816HT | 咨询 |
| Zinc Oxide Nanopowder (ZnO, 99%, 30 nm) | 5811HT | 咨询 |
| Zinc Oxide Nanopowder (ZnO, 98+%, 30 nm, hydrophilic & lipophilic) | 5812HT | 咨询 |
| Zinc Oxide Nanopowder (ZnO, 98+%, 30 nm, silicone oil coated) | 5814HT | 咨询 |
| Zinc Oxide Nanopowder (ZnO, 98+%, 30 nm, stearic acid coated) | 5815HT | 咨询 |
| Zinc Oxide Nanopowder (ZnO, 99%, 20 nm) | 5810HT | 咨询 |
| Zirconium Oxide Nanopowder (ZrO2, 99+%, 50 nm) | 5936HT | 咨询 |
| Zirconium Oxide Nanopowder (ZrO2, 99.5+%, 20 nm) | 5931HT | 咨询 |
| Zirconia Nanopowder, Yttria Doped (ZrO2/3 mol% Y2O3, 99.5+%, 15-50 nm) | 5932HT | 咨询 |
| Zirconia Nanopowder, Yttria Doped (ZrO2/5 mol% Y2O3, 99.5+%, 15-50 nm) | 5934HT | 咨询 |
| Zirconia Nanopowder, Yttria Doped (ZrO2/8 mol% Y2O3, 99.5+%, 15-50 nm) | 5933HT | 咨询 |
| Zirconia Nanopowder, Calcia Doped (ZrO2/8 mol%CaO, 99.9%, 20-30 nm) | 5934ZS | 咨询 |
| Barium Titanate Nanopowder (BaTiO3 , 99.9%, 400 nm) | 1146DY | 100g; |
| Barium Titanate Nanopowder (BaTiO3 , 99.9%, 300 nm) | 1144DY | 咨询 |
| Barium Titanate Nanopowder (BaTiO3 , 99.5%, 100-200 nm) | 1148DY | 咨询 |
| Cobalt Iron Oxides Nanopowder (CoFe2O4, 98%, 35-55 nm) | 1510FY | 25g ; 100g; |
| Cobalt-Zinc Iron Oxide Nanopowder (Co0.5Zn0.5Fe2O4, 99.5%, 30-50 nm) | 1515FY | 25g ; 100g; |
| Indium Tin Oxide Nanopowder (In2O3:SnO2 = 90wt%:10wt%, 99.99%, 20-70 nm) | 2730TN | 5g; 25g; |
| Indium Tin Oxide Nanopowder (In2O3:SnO2 = 95 wt%:5 wt%, 99.99%, 30-50 nm) | 2731BY | 5g; 25g; |
| Nickel-Zinc Iron Oxide Nanopowder (Ni0.5Zn0.5Fe2O4, 98.5%, 10-30 nm) | 4115FY | 100g; 500g; |
| *Ni80Fe17Mo3 permalloy nanopowder (99+%, 70 nm) | 9288HW | 100g; |
| Yttrium Aluminate w/Nd doped (Y2.98Nd0.02Al5O12, Nd-YAG, 99.5%, 40 nm) | 5571FY | 25g; 100g; |
| Zinc Iron Oxide Nanopowder (ZnFe2O4, 98.5%, 40 nm) | 5710FY | 100g; |
更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
Altogen Biosystems公司成立于1978年，是体外诊断工业和全球实验室原材料的主要供应商。我们为我们行业中最大的跨国公司提供广泛的人类纯化蛋白；单克隆和多克隆抗体；真菌、寄生、细菌和病毒抗原；以及用于体外诊断的疾病状态血浆。
Altogen Biosystems is a biotechnology company that develops and manufactures transfection kits for life sciences research, drug discovery and development. Altogen® In Vivo transfection reagents provide effective delivery of biomolecules into target tissues. Cell transfection kits are optimized for specific cancer cell lines and primary cell cultures. Efficient delivery of cargo molecules (DNA, RNA, proteins) enabled by advanced reagent formulation and optimized transfection protocols. Altogen Biosystems develops new in vitro and in vivo delivery technologies by applying polymer chemistry, molecular and cell biology expertise.
Altogen Biosystems公司的主要产品包括：
Fungal, protozoan, bacterial and viral antigens
Monoclonal antibodies
Polyclonal antibodies
Disease state human plasma
Purified native and recombinant human proteins
" data-original="http://atto.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Altogen Biosystems"> Altogen Biosystems
USBiological位于美国迈阿密Salem，产品包括抗体、生化试剂、细胞生物学试剂、分子生物学试剂和研究用试剂盒。
United States Biological (USBiological) is located in Swampscott in Massachusetts, USA. It's production capabilities include antibiotics, antibodies, agarose, albumin, amino acids, biochemicals, biologicals, cytokines, enzymes, media, molecular biology kits, peptides and serum. All products are supplied with certified testing results. USBio provides a huge selection of antibodies.
USBiological的主要产品包括：
（1）Antibody Catalog
Primary Antibodies
Secondary Antibodies
Isotype Controls
Epitope Tags
Matched Pair Antibody Sets
Custom Antibodies
（2）Biochemical Catalog
Amino Acids
Antibiotics & Antimycotics
Drugs & Analogues
Dyes & Stains
Fine Chemicals
Inorganics
Isotopes
Molecular Biology
Phytochemicals
（3）Biologicals Catalog
Cells & Lysates
Plasma & Serum
Tissues
（4）Cell Culture Media
Culture Media
Insect Media
Microbiological Media
Molecular Biology Media
Nematode Media
pEX™ Protein Expression
Plant Media
Yeast Media/Drop-out
（5）Molecular Biology Catalog
Cloning
Custom
Enzymes
Glycobiology
Growth Factors/Cytokines
Immunoglobulins
Infectious Disease
Lectins
Peptides
Proteins
Separation Detection
（6）Research Kits Catalog
Antibody Sets
Apoptosis
Cell Growth, Axol™
Cloning & PCR
Custom
DNA & RNA Purification
ELISA
Electrochemiluminescence
Immunohistochemistry
Immunoprecipitation
Molecular Biology
Western Blot
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://atto.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="USBiological"> USBiological
艾美捷科技代理Affinity Immuno品牌。
Affinity Immuno（AffinityImmuno）是一家位于加拿大的生物技术公司，一直专注于为生物药物研究提供高质量的试剂和服务。该公司以其专业的技术背景和丰富的产品线，在生物仿制药和单抗药研究领域赢得了广泛的认可，广泛应用于学术研究、生物技术和制药公司的研究工作。
AffinityImmuno产品包括：
（1）ELISA试剂盒：
AffinityImmuno生产的ELISA试剂盒具有高灵敏度、特异性和可重复性，用于测定临床前和临床血清血浆样本中的抗体药浓度，以及进行免疫学相关检测。这些试剂盒可用于检测多种疾病，如癌症、自身免疫病和感染病等。
（2）抗体：
公司提供多种抗体产品，包括针对癌症、自身免疫和内分泌疾病的新型靶点的抗体，以及用于细胞去除、阻断和激活研究的单克隆抗体。AffinityImmuno还可根据客户要求进行定制化开发，如多克隆抗体的制备。
（3）研发支持服务：
除了产品销售外，AffinityImmuno还提供高质量的研发支持服务，包括抗体发现、蛋白质工程和检测开发等。这些服务旨在帮助客户加速生物药物的研发进程，提高研发效率和质量。
<<< " data-original="http://atto.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Affinity Immuno品牌"> 艾美捷科技代理Affinity Immuno品牌
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年，提供近200种亚磷酰胺和核苷酸合成用固相交联单体，以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.
Berry & Associates的主要产品包括：
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://atto.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：18995651644
传真：15172469628
邮箱：sales@amyjet.com
0.2695
